BDBM658047 3-Methyl-4-(1-(2-methyl-4-(trifluoromethoxy)phenyl)-4-oxo-6-(trifluoromethyl)-1,4-dihydropyrido[3,4-d]pyrimidin-3(2H)-yl)pyridine 1-oxide::US20240083896, Example 23

SMILES Cc1cc(OC(F)(F)F)ccc1N4CN(c2cc[n+]([O-])cc2C)C(=O)c3cc(C(F)(F)F)ncc34

InChI Key InChIKey=QUAIIGSVGOKPRO-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 658047   

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658047(US20240083896, Example 23 | 3-Methyl-4-(1-(2-methy...)
Affinity DataIC50: 200nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent